CI

At a glance

ClinicalIndex Comparison Record
Phase 4Recruiting· 154 target
Drug / intervention
Dexmedetomidine +2 moredrug
Likely dose
Dexmedetomidine 0.01 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05950646
NCT05950646Phase 4RecruitingUpdate OverdueUpdated 11mo ago · Completion was 7mo ago
Enrollment Stalled
Update Overdue

Effect of Mini-dose Dexmedetomidine-Esketamine Infusion on Sleep Quality in Older Patients Undergoing Knee or Hip Replacement Surgery: A Multicenter Randomized Controlled Trial

Peking University First Hospital·interventional·Posted Jul 18, 2023·Updated Jul 30, 2025

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine, Esketamine, and 1 other intervention for Old Age and 5 related conditions. Currently recruiting, targeting 154 participants across 2 sites.

Signals

Enrollment appears stalled

Detailed Summary

Sleep disturbances are prevalent in older patients with osteoarthrosis or fracture who are scheduled for knee or hip replacement surgery. The occurrence of sleep disturbances is associated with worse outcomes including increased risk of delirium and cardiac events, and worsened functional recovery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, anxiolytic, and analgesic properties. It exerts sedative effects via activating the endogenous sleep pathways and produces a state like non-rapid eye movement sleep, which is different from opioid- and benzodiazepine-induced sedation. Esketamine is a N-methyl-D-aspartic acid receptor antagonist and has been used as an anesthetic and analgesic. Recent studies showed that low-dose esketamine has anti-depressive and sleep-promoting effects. The investigators suppose that mini-dose dexmedetomidine-esketamine combined infusion at night can improve perioperative sleep quality in patients scheduled for knee or hip replacement surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsBeijing Hospital

Timeline

Phase 4RecruitingOverdue
202420252026
First PostedJul 18, 2023
Enrollment StartNov 1, 2023
Primary CompletionNov 1, 2025
Study CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 3.0 years ago

Interventions

Dexmedetomidinedrug

Dexmedetomidine will be infused at a rate of 0.01 ml/ kg/h (0.02 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.

Esketaminedrug

Esketamine will be infused at a rate of 0.01 ml/ kg/h (5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.

Normal salinedrug

Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.